Dr. Robert Hauser, MD

Medicare patients and services

Medicare patients, 2024

119

Services billed

29,196

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 11 companies reported 299 payments worth $271,487 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 17 industry-funded studies in 2025, from 7 companies. The companies reported $1,000,584 in research payments for these studies, mostly to the institutions running them.

• A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease
  Genentech, Inc.
• Phase II study in early stage Parkinson s Disease Patients
  Roche Tcrc, Inc.
• A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)
  Teva Pharmaceuticals USA, Inc.
• Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
  AbbVie Inc. · Active, not recruiting · NCT06107426
• An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
  UCB SA · Terminated · NCT05543252
• Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
  AbbVie Inc. · Completed · NCT04750226
• A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults
  Ipsen Innovation · Recruiting · NCT06937931
• A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
  UCB SA · Completed · NCT04658186
• Fixed-Dose Trial in Early Parkinson's Disease (PD)
  AbbVie Inc. · Completed · NCT04201093
• M20-098 - Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease
  AbbVie Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Neurology clinicians in Tampa

• Faizi Ahmed, MD
• Keerthana Akkineni, M.D.
• Erfan A. Albakri, MD
• Ushtar Amin, M.D.
• Mark I. Armanious, M.D.
• Adolfo J. Baez, MD
• Kanita Beba Abadal, M.D.
• Selim R. Benbadis, MD